Studies combining Wee1 inhibitors and PARP inhibitors are being explored in ovarian cancer (NCT05198804); however the overlapping hematologic toxicities of these two agents may limit combinatorial dosing (Serra et al., 2022). Here, WEE1 is linked to ovarian carcinoma.